Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers: A phase I clinical study

Drugs in R and D

Volumn 3, Issue 5, 2002, Pages 337-348

  Castaño, Gladys ^a   Más, Rosa ^b   Fernández, Lilia ^b   López, Ernesto ^a   Gutiérrez, Juan A ^a   Illnait, José ^b   Fernández, Julio C ^b   Gámez, Rafael ^b   Alvarez, Estrella ^b  

^a Medical Surgical Research Center   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; CHOLESTEROL; D 003; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING TIME; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GINGIVA BLEEDING; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HUMAN EXPERIMENT; INFLUENZA; MALE; MEDICAL ASSESSMENT; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; SOMNOLENCE; VOLUNTEER;

EID: 0038109797     PISSN: 11745886     EISSN: None     Source Type: Journal    
DOI: 10.2165/00126839-200203050-00008     Document Type: Article

References (38)

1. Murray CJL, López AD. Alternate projections of mortality and disability by cause 1990-2020. Global Burden disease Study. Lancet 1997; 349: 1498-504
2. Brown MS, Goldstein JL. Heart Attacks: Gone with the Century. Science 1996; 272: 629-30
3. Falk E, Fernández-Ortiz A. Role of thrombosis in atherosclerosis and its complications. Am J Cardiol 1995; 75: B1-7
4. Euroaspire Study group: European Society of Cardiology survey of secondary prevention of coronary heart disease: Principal results. Eur Heart J 1997; 18: 1569-1582
5. Wood D. European and American recommendations for coronary heart disease prevention. Eur Heart J 1998; 19 Suppl A: A12-9
6. Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497
7. Pyorala K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J 1994; 15: 1300-31
8. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy-I: Prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106
9. Wilson JM, Ferguson JJ. Platelet-endothelial interactions in atherothrombotic disease: therapeutic implications. Clin Cardiol 1999; 22: 687-98
10. Scandinavian Simvastatin Survival Study Group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-1389
11. Sacks FM, Pfeffer MA, Moyé LA, et al. for the Cholesterol and Recurrent Events Trial Investigators: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 35: 1001-9
12. Tonkin A, Aylward P, Colqhoun D, et al. Prevention of cardiovascular events and deaths with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57
13. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
14. Weis S, Clearfield M, Downs JR, et al. The Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS): Primary prevention of acute major coronary events in women and men with average cholesterol. In: Grundy S. Cholesterol-lowering therapy: Evaluation of clinical trial evidence. New York, Basel: Marcel Dekker Inc, 2000: 151-172
15. The Lipid Research Clinics Coronary Primary Prevention Trial results. I: Reduction in the incidence of coronary heart disease. JAMA 1984; 251: 351-64
16. The Lipid Research Clinics Coronary Primary Prevention Trial results. II: The relationship of reduction in incidence of coronary heart disease to cholesterol lowering. JAMA 1984; 251: 365-74
17. Frick MH, Elo, O, Happa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidema. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987; 317: 1237-45
18. Troche CJ, Tacke J, Hinzpeter B, et al. Cost-effectiveness of primary and secondary prevention in cardiovascular diseases. Eur Heart J 1998; 19 Suppl C: C59-65
19. González L, Marrero D, Laguna A, et al. Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa: Laboratorios Dalmer SA, 1998 Dec 30: patent 98-2744
20. Molina V, Arruzazabala ML, Carbajal D, et al. Antithrombotic effects of D003. Pharmacol Res 2000; 42: 137-43
21. Molina V, Arruzazabala ML, Carbajal D, et al. Effects of D-003 on serum and plasma thromboxane B2 and prostaciclin levels in experimental models. Prostaglandins Leukot Essent Fatty Acids. In press
22. Gámez R, Mendoza S, Mas R, et al. Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits. Curr Ther Res Clin Exp 2000; 61: 8-16
23. Menéndez R, Mas R, Amor AM et al: Inhibition of cholesterol biosynthesis in cultured fibroblasts by D-003, a mixture of very long chain saturated fatty acids. Pharmacol Res 2001, 44: 299-304
24. Mas R. Policosanol. Drugs Future 2000; 25: 569-86
25. Gámez RA, Mas R, Noa M, et al. Six-month study of the oral toxicity of D-003 in Sprague Dawley rats. Drugs R&D. In press 2002
26. Mendoza S, Gámez R, Noa M, et al. The effects of D-003 and policosanol on the lipid profile and endothelemia cells in normocholesterolemic rabbits: a head to head comparison. Curr Ther Res Clin Exp 2001; 62: 209-20
27. Gámez R, Más R, Noa M, et al. Acute and subchronic oral toxicity of D-003 in rats. Toxicol Lett 2000; 118: 31-41
28. Gámez R, González JE, Rodeiro, I, et al. In vivo genotoxic evaluation of D-003, a mixture of very long-chain aliphatic acids. J Med Food 2001; 4: 85-92
29. Gámez R., Rodeiro I, Fernández I, et al. A preliminary evaluation of the cytotoxic and genotoxic potential of D-003: a mixture of very long chain fatty acids. Teratog Carcinog Mutagen 2001. In press
30. Arruzazabala ML, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res 1994; 27: 205-8
31. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem 1981; 27: 838-41
32. Friedewald WT, Levy IR, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502
33. O'Brien PC, Shampo MA. Statistical considerations for performing multiple tests in a single experiment. Comparing two therapies with respect to several endpoints. Mayo Clin Proc 1988; 63: 1140-3
34. Schafer AI. Antiplatelet therapy. Am J Med 1996; 101: 199-209
35. McTavish D, Faulds D, Goa KL. Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders. Drugs 1990; 40: 238-59
36. Coukell AJ, Marham A. Clopidogrel. Drugs 1997; 54: 745-50
37. Menéndez R, Mas R, Pérez Y, et al. Inhibition of rat lipoprotein lipid peroxidation by the oral administration of D-003. Can J Physiol Pharmacol. In press
38. Aviram M. Macrophages, LDL oxidation and atherosclerosis. In: Jacotot B, Mathé D, fruchart JC, editors. Atherosclerosis XI International Congress. Series 1155. Singapore: Excerpta Medica Elsevier Science, 1998: 483-492